

Urokinase Treated IVH Clearance Rate




Fig. 1

Effect of Urokinase on Clot Lysis




Fig. 2

10/509694

Thrombolysis




Fig. 3


BEST AVAILABLE COPY

Fig. 4

IVH Outcomes

Safety Monitoring: Primary Endpoints

39 Patients Enrolled



BEST AVAILABLE COPY

Rapid Clot Lysis—IVH





Fig. 5

10/509694

Relation Between Clot Lysis and Consciousness Level

Fig. 6



10/509694

Relation Between Clot Lysis and Consciousness Level

Fig. 7




Fig. 8

Predicted Probability of Death v. Actual Death in Patients Receiving Urokinase/Placebo

STUDY/PATIENT GROUP	SAMPLE SIZE	AVERAGE ICH SIZE	AVERAGE GCS	AVERAGE PULSE PRESSURE	PREDICTED PROBABILITY OF MORTALITY	ACTUAL PROBABILITY MORTALITY	P-VALUE FOR MORTALITY REDUCTION
PILOT UK/ALL PATIENTS	12	34.8	3.93	9	92	58.00%	25% 0.022
RANDOMIZED UK/UK PATIENTS	6	66.8	3.71	8	97	38.00%	0% 0.057
RANDOMIZED UK/PLACEBO PATIENTS	5	41.5	13.3	8	95	58.00%	20% 0.103
RANDOMIZED UK/ALL PATIENTS	34	53.8	4.17	8	86	77.71%	23.5% <0.00001